Shire’s haemophilia A gene therapy wins Orphan status – PharmaTimes
PharmaTimes |
Shire's haemophilia A gene therapy wins Orphan status
PharmaTimes Shire's gene therapy candidate SHP654, an investigational factor VIII gene therapy for the treatment of haemophilia A, has been awarded Orphan Drug Designation by US regulators. The move qualifies Shire for access to various incentives designed to … |
